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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

PHARMACOGENOMICS AND THE GENETIC INFORMATION
NONDISCRIMINATION ACT OF 2008: LEGISLATION LIMITATIONS AND
ITS IMPACT ON PGx RESEARCH AND CLINICAL OPPORTUNITY
I. INTRODUCTION
Pharmacogenomics (“PGx”) can be defined as “a science that examines
the inherited variations in genes that dictate drug response and explores the
ways these variations can be used to predict whether a patient will have a
good response to a drug, a bad response to a drug, or no response at all.”1
To be most effective, PGx research requires a large population sample with
However, genetic
diverse racial, ethnic, and genetic backgrounds.2
discrimination has become the most commonly cited reason for individuals
to forgo voluntary research.3
Through the Genetic Information
Nondiscrimination Act of 2008 (“GINA”), Congress has attempted to
alleviate this fear by providing a federal law that bans genetic discrimination
by employers and insurance companies.4
However, the goal of increasing voluntary participation in PGx research
may never fully come to fruition because a lack of research participation
likely reaches far beyond the fear of genetic discrimination. Numerous
other psychological and social risks, including fears of interference with

1. National Center for Biotechnology Information, Just the Facts: A Basic Introduction to
the Science Underlying NCBI Resources, http://www.ncbi.nlm.nih.gov/About/primer/
pharm.html (last visited Mar. 17, 2010).
2. See Gail Henderson et al., Great Expectations: Views of Genetic Research Participants
Regarding Current and Future Genetic Studies, 10 GENETICS MED. 193, 193 (2008).
3. See MICHELE SCHOONMAKER & ERIN D. WILLIAMS, GENETIC TESTING: SCIENTIFIC
BACKGROUND AND NONDISCRIMINATION LEGISLATION 24 (2006) (noting that “fear caused by
the possibility that a job may be lost or insurance may be cancelled—whether real or
perceived—is the primary reason individuals refrain from seeking what could be a beneficial
genetic test in clinical or research settings”); see generally Genetic Information
Nondiscrimination Act of 2008 (GINA), Pub. L. No. 110–223, § 2, 122 Stat. 881 (2008) (to
be codified in scattered sections of 26 U.S.C., 29 U.S.C., and 42 U.S.C). Congress enacted
GINA after being informed about cases of genetic discrimination. GINA, 122 Stat. at 88283.
4. See generally GINA, 122 Stat. at 881-921. GINA provides uniform federal
legislation that establishes basic standards aimed “to fully protect the public from
discrimination and allay their concerns about the potential for discrimination, thereby allowing
individuals to take advantage of genetic testing, technologies, research, and new therapies.”
GINA §2, 122 Stat. at 882-83.
153
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familial relationships,5 concerns that the individual is better off not knowing
the results of the genetic test,6 and distrust towards medical research may
dissuade individuals from participating in research and clinical
opportunities.7
While GINA has taken a substantial step forward in protecting
individuals from genetic discrimination, and thus calming some of the
American public’s fears, PGx research will only reach its full potential when
other risks are clearly identified and addressed through public education
and public participation in the decision-making processes.8 For minority
participants, community involvement that promotes “engagement, dialogue,
and feedback” is one approach to better understand the barriers that
influence minority participation in genetic research.9 Beyond the protections
ensured by GINA, these community programs may also help to advance the
emerging scientific field of PGx.
Sections II and III of this comment focus on the science and underlying
technology of PGx research, as well as its future goals. These sections also
identify several current clinical uses of PGx technology and discuss hurdles
PGx faces in the coming years. Section IV discusses the importance of
including minority populations in PGx research populations and the
controversy surrounding race as a biological classification. Section V
illustrates current obstacles of PGx research, including specific instances of
genetic discrimination, while section VI addresses failed legislative efforts at
combating discrimination. Next, section VII describes pertinent provisions of
GINA, the most recent non-discrimination effort. Section VIII analyzes the
numerous limitations of GINA, including the legislature’s failure to address
other obstacles to genetic research participation, especially among minority
populations. Finally, section IX explains approaches to addressing the
others barriers of genetic and clinical research, all of which share the goal
of increasing minority research participation.
This comment attempts to answer two central issues surrounding PGx:
First, how does GINA help further the goals of PGx and how is the
legislation limited in clinical practice? Second, beyond GINA, what other
barriers to genetic research need to be addressed so that the future of PGx
can continue to develop in research and clinical application?
5. See SCHOONMAKER & WILLIAMS, supra note 3, at 23-24 (noting that, for example,
some family members may not want to know the results of paternity tests).
6. See Henderson et al., supra note 2, at 196.
7. Barbara A. Noah, The Participation of Underrepresented Minorities in Clinical
Research, 29 AM. J.L. & MED. 221, 229-31 (2003).
8. See Paul Slovic, Trust, Emotion, Sex, Politics, and Science: Surveying the Risk
Assessment Battlefield, 1997 U. CHI. LEGAL F. 59, 95–96 (1997).
9. See Giselle Corbie-Smith et al., Distrust, Race, and Research, 162 ARCHIVES INTERNAL
MED. 2458, 2462 (2002).
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II. PHARMACOGENOMICS: HISTORY AND BASIC SCIENCE
PGx aims to “identify and quantify the association between variations in
DNA sequence and variations in the drug response phenotype (i.e. the
‘genotype-phenotype correlation’).”10 The study of PGx merges the fields of
pharmacology, genetics, and human genomics.11 The research goals of
PGx are focused on defining drug absorption, drug safety, and drug efficacy
for a particular genotype in order to move from the current “one size fits all”
standard for prescription drugs, to a more precise “personalized drug”
standard.12 In doing so, the pharmaceutical industry hopes to reduce, if not
eliminate, adverse drug reactions (“ADRs”).13
The underlying science of PGx, although relatively new to most
physicians and patients, has been studied since the early 1900s.14 In 1902,
Archibald Garrod theorized that alcaptonuria was caused by a genetic
variation in the metabolic pathway that broke down toxic substances in the
body.15 Later, during World War II, specific drug reactions based on
inherited genetic variations were recorded for the first time.16 Then in 1959
the term “pharmacogenetics” was first used by Fredrich Vogel.17 Even
though the two terms are sometimes used interchangeably in the literature,
“pharmacogenetics is generally recognized as the study of how individual
genetic differences affect drug response [whereas] pharmacogenomics
encompasses the role of the whole genome in pharmacology and drug
design.”18

10. DEP’T OF HEALTH & HUMAN SERV., SECRETARY’S ADVISORY COMM. ON GENETICS, HEALTH,
& SOCIETY, REALIZING THE POTENTIAL OF PHARMACOGENOMICS: OPPORTUNITIES AND CHALLENGES
14 (2008) [hereinafter HHS].
11. Id. at 9.
12. O. P. Corrigan, Pharmacogenetics, Ethical Issues: Review of the Nuffield Council on
Bioethics Report, 31 J. MED. ETHICS 144, 144–45 (2005). See also Lawrence J. Lesko et al.,
Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision
Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop, 43 J. CLINICAL
PHARMACOLOGY 342, 343 (2003).
13. Corrigan, supra note 12, at 145.
14. See Berrie Rebecca Goldman, Pharmacogenomics: Privacy in the Era of Personalized
Medicine, 4 NW. J. TECH. & INTELL. PROP. 83, 85 (2005).
15. Penelope K. Manasco & Teresa E. Arledge, Drug Development Strategies, in
PHARMACOGENOMICS: SOCIAL, ETHICAL, AND CLINICAL DIMENSIONS 83, 89 (Mark A. Rothstein
ed., 2003).
16. See Goldman, supra note 14, at 86 (noting that during World War II, some soldiers
who were treated with an anti-malarial medication developed anemia due to an underlying
genetic deficiency of the glucose-6-phosphate dehydrogenase enzyme).
17. Barbara Ann Binzak, How Pharmacogenomics Will Impact the Federal Regulation of
Clinical Trial and the New Drug Approval Process, 58 FOOD & DRUG L.J. 103, 104 (2003).
18. HHS, supra note 10, at 9. Pharmacogenomics can be further defined as “the study of
how individual genetic differences affect drug response . . . This definition encompasses
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Today, the Human Genome Project (“HGP”), spearheaded by the
Department of Energy (“DOE”) and the National Institutes of Health (“NIH”),
has helped advance the field of PGx through the identification of
approximately 25,000 genes in human DNA.19 “More than 1.4 million
single-nucleotide polymorphisms [SNPs] were identified in the initial
sequencing of the human genome, with over 60,000 of them in the coding
region of genes.”20 Individualized PGx information is gathered through
comparing an individual’s single nucleotide sequence to the nucleotide
sequence that was discovered from the HGP to see if the DNA “matches”
the normal sequence.21 Because SNPs may affect drug-metabolizing
enzymes, understanding SNPs will be an important tool in predicting an
individual’s response to certain medications.22 The ultimate aim is that
physicians will use an individual’s genotype to determine which drugs and
dosages have been shown to be safe and effective through clinical drug
trials that utilized PGx data.23 Likewise, those individuals without the
requisite genotype will be able to forgo unnecessary and possibly unsafe
treatment.24 PGx aims to bring previously rejected drugs into the market
place by making them safe for a genetically targeted population,25 and also
to introduce newly formulated drugs that target specific genotypes.26
Therefore, PGx will change the pharmaceutical industry’s approaches to
drug development, clinical trials, and marketing.27 In return, it is predicted

interindividual genetic differences such as variation in [DNA] sequence, gene expression, and
copy number related to an individual’s metabolism of drugs (pharmacokinetics) or . . .
physiological response to drugs (pharmacodynamics).” Id. at 9-10. For the purpose of this
comment, pharmacogenomics and pharmacogenetics are used interchangeably and denoted
by the short-form PGx.
19. Binzak, supra note 17, at 109; William E. Evans & Howard L. McLeod,
Pharmacogenomics—Drug Disposition, Drug Targets, and Side Effects, 348 NEW ENG. J. MED.
538, 538 (2003).
20. Evans & McLeod, supra note 19, at 538. See also Biznak, supra note 17, at 109.
21. See Binzak, supra note 17, at 109.
22. Id. at 110.
23. Teresa Kelton, Pharmacogenomics: The Rediscovery of the Concept of Tailored Drug
Therapy and Personalized Medicine, HEALTH LAW., Jan. 2007, at 1, 3.
24. Id.
25. Alan Dove, Pharmacogenomics Regulations Take Flight, DRUG DISCOVERY & DEV., Jan.
2006, at 40, 41.
26. See HHS, supra note 10, at 28.
27. See Binzak, supra note 17, at 113 (discussing that PGx will change the
pharmaceutical industry by allowing companies to identify a new drug compound that will
interact with a person based on genotype, “saving” drugs that had previously been rejected by
the FDA, using diagnostic tests in drug trials for drugs that have already been approved, and
performing follow-up trials on specific subpopulations as ADRs are reported).
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that PGx could save the industry $300 million a year and each drug will
take two fewer years to develop.28
III. CLINICAL DRUG DEVELOPMENT, PGX RESEARCH, AND CLINICAL OPPORTUNITY
Currently, physicians engage in a “trial and error” approach when
determining what drugs to prescribe to their patients.29 The goal is always
to find a safe and effective drug; however this goal may be thwarted by side
effects and ADRs.30 “Although ADRs can result from a variety of factors,
genetic variations of drug-metabolizing enzymes have been highly
correlated with ADRs in some instances.”31 ADRs pose extreme risks to
patients; more than two million serious adverse events occur each year,
resulting in more than 135,000 deaths.32 Patients that are hospitalized due
to ADRs face an average of 1.7–2.2 days in the hospital and between
$2,000 and $2,600 in medical care costs.33 Further, ADRs are the primary
reason medications are withdrawn from the market.34
The trial-and-error approach also causes physicians to prescribe an
estimated three million incorrect or ineffective medications every year.35
Currently, there is no trial and error drug that is 100 percent safe and
effective for use with 100 percent of the population. Partially as a result of
ineffectiveness, patients with chronic conditions, for example, often do not
follow through with their medication treatment.36
The first step in attempting to curtail the trial and error approach of
prescribing medication is to gather PGx data for clinical drug trial
participants. During Phase I trials, a small population of healthy individuals
are studied to identify their tolerability to investigative drugs, which helps
determine associated ADRs and how drugs should be dosed.37 Next, Phase
II trials include several hundred to a thousand subjects who have the disease
that the investigative drug seeks to treat.38 During this phase, PGx data can
be used to identify a correlation between the safety and efficacy of the drug

28. Id.
29. Kelton, supra note 23, at 1.
30. Id.
31. See HHS, supra note 10, at 11; see also Biznak, supra note 17, at 110 (noting that
CYP3A, a drug metabolizing enzyme, is involved in the breakdown of up to fifty percent of
clinically therapeutic agents).
32. Kelton, supra note 23, at 6.
33. Id.
34. HHS, supra note 10, at 11.
35. Id.
36. Id., at 12-13 (noting that “[h]alf of patients with chronic health conditions discontinue
their medications after 1 year”).
37. See Manasco & Arledge, supra note 15, at 89.
38. Id. at 90.
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and the genotypic variations that may explain ineffective or unsafe
reactions.39 Further, this type of PGx data can later be used to develop
commercial tests that identify the variation in patients.40 Finally, during
Phase III trials, PGx data can be used to identify more stringent inclusion
and exclusion participation criteria.41 This hopefully will reduce the
population size, make the trial more effective (because all of the participants
will or will not have the particular genetic variation that reacts with the
drug), and decrease research costs. Drugs developed with PGx data will not
be 100 percent effective, nor will they have zero incidence of ADRs.
However, PGx drugs will be marketed specifically to those patients who have
the genotype that reacts to the particular drug, and in doing so, will
presumably make drugs on the market more safe and effective.
With regard to drug labeling, by using drug labels to warn patients of
risks to specific genotypes and by requiring genetic tests prior to drug
treatment, pharmaceutical companies may be able to reduce their liability
and avoid lawsuits.42 This seems practical given the relative ease of SNP
genotyping.43 However, the most recent data indicates that only 121 drug
labels (out of 1200 drug labels reviewed) contained pharmacogenomic
information.44 Even though PGx data is available for seventy-one percent of
the top 200 prescribed drugs, only three actually contain package inserts.45
Federal law requires that certain information should be included in the
indications and usage section of the drug label “[i]f evidence is available to
support the safety and effectiveness of the drug only in selected subgroups
of the larger population . . .” 46 or “[i]f specific tests are [needed] for

39. Id.
40. Id. at 91.
41. See id.
42. See, e.g., Binzak, supra note 17, at 107 (discussing lawsuits brought against
SmithKline Beecham claiming that LYMErix vaccine should have been labeled to indicate a
possible ADR for people with the HLA-DR4+ genotype).
43. See David J. Wu, A Pharmacogenomics Standard for FDA Drug Approval: Arbitrary
and Capricious or Safe and Effective?, 23 BIOTECH. L. REP. 733, 738 (2004) (stating an
individual’s genotype, and thus any variant SNP, can be determined within “minutes rather
than hours or days”).
44. See Felix W. Frueh et al., Pharmacogenomic Biomarker Information in Drug Labels
Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use,
28 PHARMACOTHERAPY 992, 994 (2008).
45. HHS, supra note 10, at 76 (citing Issam Zineh et al., Discordance Between Availability
of Pharmacogenetics Studies and Pharmacogenetics-Based Prescribing Information for the Top
200 Drugs, 40 ANNALS PHARMACOTHERAPY 639, 639 (2006) (stating that “pharmacogenetics
data are available in only about 2% of all drug package inserts (PIs) and that less than 1% of
PIs have pharmacogenetics data sufficient to guide therapy”)).
46. 21 C.F.R. § 201.57(c)(3)(i) (2006).
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selection or monitoring of the patients who need the drug.”47 Undoubtedly,
this may include data gathered through PGx research.
Recently, the FDA approved Herceptin®, making it the first drug to be
approved based upon PGx data.48 It was approved for patients with breast
cancer who over-express the HER-2/neu protein.49 The label now advises
patients to undergo a genetic test prior to taking the medication,
“HERCEPTIN should only be used in patients whose tumors have HER2
protein overexpression [sic].”50 Ideally, through PGx data, researchers will
be able to specifically pinpoint the type of genotypic variations that cause
some types of ADRs, and address them on the drug label.
The clinical applications of PGx research in diagnostic testing have thus
far been limited.51
The decision of whether a pharmacogenetic and pharmacogenomic test is
necessary prior to dosing will be dependent on many factors, including the
following: (1) if safety, the seriousness of the adverse event; (2) if efficacy,
the consequences of nonresponse; (3) the incidence of the clinical outcome;
(4) the variability in the clearance of the drug; (5) how well an adverse event
can be managed . . . (6) need for education of physicians and third-party
payers; and (7) feasibility of accessing and using the test in clinical
practice.52

Regardless of clinical applications, research on Cytochrome p450
(“CYP450”) has already proven to be important.53 CYP450 is a protein that
metabolizes more than twenty-five percent of all prescription drugs.54
Mutations in the CYP450 genes cause certain drugs to metabolize at
drastically different rates.55 This results in a less effective and more
dangerous drug because some patients will not be able to eliminate the
medication, which may become toxic to the body.56 On the other hand, if
drugs are eliminated from the body too quickly they may not have any
physiological response.
Consequently, in 2004, the AmpliChip®

47. 21 C.F.R. § 201.57.
48. Kelton, supra note 23, at 5.
49. GENENTECH, INC., HERCEPTIN® (2000) (package insert), available at http://www.fda.
gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/A
pprovalApplications/TherapeuticBiologicApplications/ucm092760.pdf.
50. Id.
51. See HHS, supra note 10, at 17.
52. See Lesko, supra note 12, at 351.
53. See HHS, supra note 10, at 11.
54. See Kelton, supra note 23, at 5.
55. Id.
56. See Yusuke Nakamura, Pharmacogenomics and Drug Toxicity, 359 NEW ENG. J. MED.
856, 857 (2008); Kelton, supra note 23, at 5.
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Cytochrome p450 Genotyping Screening Test was designed.57 The test
detects mutations in two CYP450 genes58 allowing a physician to determine
the right drug dose for the patient based on how the patient’s body
expresses CYP450.59 Over half of all drug labels available with PGx data
reference CYP2D6 or CYP2C19.60
Particularly, the CYP2D6 enzyme is involved in metabolizing seventy-five
percent of all psychotropic drugs.61 One such drug, risperidone, is poorly
metabolized in seven percent of Caucasians and one to two percent of other
races.62 Such a deficiency, if gone unidentified, can cause severe ADRs.63
An example of this reaction is found in the case of Michael Conroy-Adams,
a nine-year old boy who was prescribed Prozac.64 Michael had a genetic
variation on the CYP2D6 receptor that caused his body to metabolize the
drug slowly.65 Sadly, this led to a fatal accumulation of toxic substances in
his body.66 If a genetic test had been done prior to his prescription, instead
of during an autopsy, the variant may have been discovered and Michael
may still be alive.
Similarly, the CYP2C19 enzyme metabolizes warfarin, a drug prescribed
for people at risk for blood clots that works by blocking the Vitamin K
pathway.67 Individuals whose genotypes are homozygous for the *3 allele
of the gene are slow metabolizers of warfarin and do not clear the drug
properly.68 This results in a toxic buildup of the drug that can lead to an
ADR.69 Therefore, the identification of the CYP450 gene, its variants, and
its associated SNPs, make it clear that genetic tests developed through PGx
research can be life-saving.

57. Id.
58. Id.
59. See generally Wu, supra note 43, at 745 (arguing that FDA should require
mandatory genetic testing and data submission for CYP450 genes because they are highly
polymorphic and metabolize a large percentage of drugs at possibly different rates).
60. See Frueh, supra note 44, at 995.
61. See John Bray et al., 15 J. PSYCHIATRIC & MENTAL HEALTH NURSING 357, 358 (2008).
CYP450 enzymes are also responsible for metabolizing Adderall®, Coreg®, Effexor®,
Inderal®, Paxil®, Prozac®, Strattera®, Toprol®, Tussionex®, and Zofran®. HHS, supra
note 10, at 11.
62. See Bray, supra note 61, at 358.
63. Id.
64. Wu, supra note 43, at 733.
65. Id.
66. Id.
67. See Evgeny Krynetskiy & Patrick McDonnell, Building Individualized Medicine:
Prevention of Adverse Reactions to Warfarin Therapy, 322 J. PHARMACOLOGY & EXPERIMENTAL
THERAPEUTICS 427, 428 (2007).
68. HHS, supra note 10, at 15.
69. See Krynetskiy & McDonnell, supra note 67, at 428.
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Another current application of PGx concerns a genetic test that
determines whether or not patients have an inherited variation in the enzyme
thiopurine methyltransferase (“TPMT”) which metabolizes a drug used to
treat acute lymphoblastic leukemia in children.70 Children who have a
germline variation do not metabolize the drug as quickly or effectively as
those without the variation.71 This results in toxic levels of the drug in the
bloodstream, inevitably leading to destruction of bone marrow and possibly
death.72 When children are tested for the TPMT variation, their physicians
can better determine the appropriate course of treatment, type of drug, and
necessary dosage. Such a test will hopefully result in less pain and suffering
for children with acute lymphoblastic leukemia.
The FDA may be partially to blame for the low utilization of PGx
research and application. The FDA issued guidance documents for
submitting PGx data in investigational new drug applications (“INDs”) in
March, 2005.73 These guidance documents amount to nothing more than
suggestions for the pharmaceutical industry to follow, and as such, are
completely voluntary.74 If the FDA made PGx data a requirement rather
than a recommendation, the pharmaceutical industry would have no choice
but to include PGx research in clinical drug trials.75 Indirectly, the
requirements may result in package inserts, drug labels, and diagnostic
genetic tests indicating safety and efficacy based on PGx data. In this
regard, some argue that the FDA is not doing enough to keep patients safe
even though it possesses the authority to do so.76
IV. PGX AND MINORITY POPULATIONS
Throughout drug development, PGx data will be useful in defining the
precise genotypes that are likely to respond to specific drugs in a certain
way.77 Because genetic SNPs can vary between racial groups, a widely
diverse population sample during clinical drug trials will be necessary to
realize the full potential of PGx.78 As discussed with the CYP2D6 enzyme,

70.
71.
72.
73.

HHS, supra note 10, at 14.
Id. at 14-15.
Id.
DEP’T OF HEALTH & HUMAN SERV., FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
PHARMACOGENOMIC DATA (2005), http://www.fda.gov/downloads/RegulatoryInformation/
Guidances/UCM126957.pdf.
74. Id. at 1.
75. See Dove, supra note 25, at 42.
76. See Wu, supra note 43, at 734.
77. HHS, supra note 10, at 23.
78. See Osagie K. Obasogie, Beyond Best Practices: Strict Scrutiny as a Regulatory Model
for Race-Specific Medicines, 36 J.L. MED. & ETHICS 491, 492 (2008) (discussing that genetic
variants which appear at a frequency of less than twenty percent in a racial group are likely to
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the way in which individuals metabolize a drug can differ widely between
racial and ethnic subpopulations, thus affecting drug safety and efficacy.79
Since genotypic variation exists between racially and ethnically diverse
populations, gathering enough research data to implement population-wide
application poses a significant hurdle to PGx research and its application.
BiDil® is a modern example of PGx research benefitting a racially
diverse population. BiDil, patented and marketed by NitroMed, was
approved by the FDA in 2005 to treat heart disease in African Americans.80
BiDil has been in existence in one form or another since 1980, when trials
were first conducted on the drug.81 The drug’s medical use was largely
discovered by the African-American Heart Failure Trial (A-HeFT), which
enrolled 1,050 self-identified African-American participants.82 The trial
found that the placebo group showed a higher rate of mortality and a lower
quality of life.83 BiDil was shown to reduce death rates in heart failure
patients by forty-three percent.84 Based on this data, NitroMed ended the
trail early because it was determined it would be unethical to continue

be contained within that group; Africans have several low-frequency genetic variants and thus,
genetic variants are common and contained within the group).
79. See Bray, supra note 61, at 358 (discussing that the incidence of poor metabolism of
CYP2C19 ranges from fifteen to one hundred percent in certain Asian subgroups and only
three to six percent in Caucasians); Vural Ozdemir et al., Race as a Variable in
Pharmacogenomics Science: From Empirical Ethics to Publication Standards, 18
PHARMACOGENETICS & GENOMICS 837, 837 (2008) (discussing that there is an “unequal
distribution of disease-associated alleles for certain recessive disorders such as Tay-Sachs
disease and sickle cell anemia among racially defined populations”); HHS, supra note 10, at
46 (discussing a Washington, D.C. area study that found two percent of Ashkenazi Jews in the
area carried mutations in their BRCA 1 and BRCA 2 genes, conferring an increased risk of
breast and ovarian cancer by age 70).
80. Obasogie, supra note 78, at 493. See also Stephanie Saul, F.D.A. Approves a Heart
Drug for African Americans, N.Y. TIMES, June 24, 2005 (discussing that BiDil is thought to
work by increasing levels of nitric oxide in the body, which is more often deficient in African
Americans, thereby relaxing blood vessels and making it easier for the heart to pump blood),
available at www.nytimes.com/2005/06/24/health/24drugs.html?_r=1&scp=1&sq=F.D.A..
%20Approves%20a%20Heart%20Drug%20for%20African%20Americans&st=cse.
81. See generally Sharona Hoffman, “Racially-Tailored” Medicine Unraveled, 55 AM. U.
L. REV. 395, 400-01 (2005-06). BiDil consists of a combination of two drugs, hydralazine
and isosorbide dinitrate. Id. at 400. The first studies on the drugs ran from 1980 to 1991
during the Vasodilator Heart Failure Trials. Id. at 401. The trials included black and white
participants but did not report racial distinctions in drug response rates. Id.
82. Obasogie, supra note 78, at 493.
83. Id.
84. See Saul, supra note 80.
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giving the control group a placebo while the other group was benefitting
substantially from the drug.85
“Race-based medicine,” as it has become known, is not without
controversy.86 Some social scientists denounce the use of race as a factor
for genetic based research. They argue that race-based research lends itself
to race stigmatization, stereotyping, and more racial disparity, over forty
years after the Civil Rights movement.87 Race-based medicines are
controversial, with Bidil serving as a prime example.88 Generally, critics are
concerned that pharmaceutical companies and researchers will begin to use
race as a substitute for genotyping and that race will be used as a
genetically-based categorization.89 Critics argue that such categorization is
unfair. “Race, at the continental level, has not been shown to provide a
useful categorization of genetic information about the response to drugs,
diagnosis, or causes of disease.”90 However, as the approval of BiDil has
shown, race-based medicine has advantages and therefore needs research
participant support in order to further understand genetic differences among
races. The effect of such genetic research on various races and ethnicities
may ensure that medical therapy and PGx will better suit the general
population.91
V. OBSTACLES: CONSENT, PRIVACY, AND GENETIC DISCRIMINATION
PGx faces numerous obstacles in the years and decades that lie ahead.
When participants engage in PGx research, they effectively give permission
for their genetic information to be used in numerous ways, some of which

85. See Andrew Pollack, Drug Approved for Heart Failure in Black Patients, N.Y. TIMES,
July 20, 2004, at C1.
86. See Obasogie, supra note 78, at 491 (noting that there is a “heated debate in
scientific and bioethical communities over when and how race should be used in biomedical
research”).
87. See generally Dorothy E. Roberts, Is Race-Based Medicine Good for Us?: African
American Approaches to Race, Biomedicine, and Equality, 36 J.L. MED. & ETHICS 537, 537
(noting that there are several different approaches to race-based medicine).
88. See generally Hoffman, supra note 81, at 405-06 (discussing that critics of BiDil
argue that the trial results are not significant because the treatment combination was only
studied in self-identified African Americans, and therefore it would be erroneous to conclude
that the treatment is effective only in that population).
89. See Saul, supra note 80.
90. Richard S. Cooper et al., Race and Genomics, 348 NEW ENG. J. MED. 1166, 1168
(2003).
91. See Alastair J.J. Wood, Racial Differences in the Response to Drugs—Pointers to
Genetic Differences, 344 NEW ENG. J. MED. 1393, 1394-95 (2001) (arguing that genetic
differences among racial groups support the use of race-based genetics in medical research
and drug therapy).

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

164

SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY

[Vol. 3:153

are not known at the time of consent.92 The patient/participant, as with any
medical procedure, must give complete informed consent without
coercion.93 However, when PGx testing is required for treatment, patients
may believe that they have to submit their genetic fingerprint in order to
have their medical needs met.94 Consenting to genetic research has the
potential to forever link participants to the results of the research by way of
their genetic profiles. Because people can be easily identified by only a few
SNPs, privacy is a continuous issue.95 Consent and privacy are implicated
even further when a genotyping test implies a risk for future disease, which
may lead to unintended consequences, such as stigmatization for the patient
and his or her family.96
Another commonly cited hurdle to reaching the full potential of PGx is
the fear that patients’ genetic information will be misused.97 Patients may
fear that if a genotyping test reveals a genetic disease, they or their family
members will be discriminated against by insurance companies and
employers.98 The effect could be a reluctance to submit to PGx clinical
research for drug development and treatment. Historically, some form of
genetic discrimination has occurred in the United States since at least the
early 1900’s. During this time, states enacted laws requiring people with
physical and mental handicaps to undergo sterilization so that they were not
able to reproduce.99 Indiana was the first state to do so in 1907.100 While
states have since enacted laws abolishing and repealing state sterilization
laws,101 perceived and actual genetic discrimination persists.
Today, genetic discrimination occurs primarily with employment and
medical insurance. For employers, the rationale for such discrimination is
simple; not hiring, firing, or not promoting a person with a genetic
predisposition to a disease reduces labor and medical expenses.102
92. See Corrigan, supra note 12, at 146 (noting that patients agree to the participating in
the clinical drug trial, a genetic test pertaining to the drug effect, and other genetic tests to be
used in future PGx studies).
93. See id.
94. See HHS, supra note 10, at 42.
95. Id. at 41.
96. Wu, supra note 43, at 745. See GINA, Pub. L. No. 110-223, § 2, 122 Stat. 881,
882 (2008) (discussing how state-imposed mandatory testing of African Americans for sickle
cell disease in the 1970s led to discrimination and fear).
97. GINA § 2,122 Stat. at 881-82.
98. See Goldman, supra note 14, at 83.
99. See GINA § 2, 122 Stat. at 882.
100. GINA § 2, 122 Stat. at 882.
101. GINA § 2, 122 Stat. at 882.
102. See COUNCIL FOR RESPONSIBLE GENETICS, GENETIC DISCRIMINATION: POSITION PAPER
(2001) [hereinafter CRG], http://www.councilforresponsiblegenetics.org/pageDocuments/2R
SW5M2HJ2.pdf.
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Specifically, if the employee becomes sick, he or she is likely to be less
productive, absent from work more often, and have higher insurance
costs.103 Similarly, the insurance industry operates on reducing risk in order
to lower benefit payments.104 Naturally, reducing the number of insureds
who have a greater chance of becoming sick in the future is a way for the
insurance industry to meet this goal.105
Americans seem to understand the positive future impact of genetic
testing, and particularly, PGx. In 2007, the Genetics and Public Policy
Center at John Hopkins University completed a survey highlighting
Americans’ attitudes toward genetic testing.106 The survey found that “more
than 90 percent support the use of genetic testing by researchers to find new
ways to diagnose, prevent or treat diseases.”107 Further, “more than 90
percent of Americans support the use of genetic testing by doctors to identify
a person’s risk for future disease when there are treatments or medicines
available, or to determine the risk of having a bad reaction to a particular
medicine.”108 However, eighty-one percent oppose the use of genetic
testing by employers “to make decisions about hiring and promotion” and
eighty-five percent oppose the use of genetic testing by health insurers “to
determine who [sic] to insure or how much to charge.”109 These statements
reflect the fear that information can be used adversely by employers and
insurance companies, which may result in a decision to forego participating
in genetic research and testing.110
Despite assertions that genetic discrimination does not occur, others
argue it is a reality and is significantly underreported due, in part, to low
utilization of genetic testing, fear of adverse insurance and employment
actions, and privacy concerns.111 The Council for Responsible Genetics has

103. Id.
104. See id.
105. See id.
106. See The Genetic Nondiscrimination Act: Hearing on H.R. 493 Before the Subcomm.
on Health of the H. Energy and Commerce Comm., 110th Cong. 3 (2007) [hereinafter
Hearing] (testimony of Kathy Hudson, Ph.D., Director, Genetics and Public Policy Center, John
Hopkins University).
107. Id.
108. Id.
109. Id. at 5.
110. See Lauren J. Sismondo, GINA, What Could You Do for Me One Day?: The Potential
of the Genetic Information Nondiscrimination Act to Protect the American Public, 21 WASH. U.
J.L. & POL’Y 459, 462 (2006) (discussing that fear of misuse of genetic information stems
partially from the fact that genetic information is important to “relatives, employers, insurers,
researchers, and the government”).
111. See Karen H. Rothenberg & Sharon F. Terry, Before It’s Too Late—Addressing Fear of
Genetic Information, 297 SCIENCE 196, 196-97 (2002); see generally Jill Gaulding, Note,
Race, Sex, and Genetic Discrimination in Insurance: What’s Fair?, 80 CORNELL L. REV. 1646,
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documented a wide range of cases of employment and insurance
discrimination.112 In one case, a social worker mentioned during an
informal conversation at work that her mother died of Huntington’s disease
and that she had a fifty percent chance of developing the condition.113 One
week later, the social worker was fired from her job even though her
performance was well above average.114 With the tremendous amount of
personal and sensitive information that can be determined from a genetic
test, the importance of protecting patients and research subjects is
irrefutable.
While no per se genetic discrimination case has been decided in the
United States, several have been filed under various legal theories, and
others have implicated such discrimination.115 In Norman-Bloodsaw v.
Lawrence Berkeley Laboratory, former employees of a government-run
research institute brought a lawsuit under Title VII of the Civil Rights Act and
the Americans with Disabilities Act (ADA).116 They alleged several violations
arising from employment entrance examination requirements to submit to
testing for sickle cell disease, syphilis, and pregnancy.117 In ruling on behalf
of the former employees, the court noted that “[o]ne can think of few subject
areas more personal and more likely to implicate privacy interests than that
of one’s health or genetic make-up.”118 The court went on to state that the
types of information revealed from these tests were more personal than
other general medical information and enjoy “the highest expectations of
privacy.”119 Specifically, the court determined that carrying the sickle cell
trait has implications of family history and reproductive decisions, and may
not be necessary for a routine physical examination.120

1665-66 (1995). Gaulding claims that insurers practice “fair discrimination” when they use
predictive genetic tests in underwriting because it is the best indication of an insured’s
expected loss. Id. at 1665. For example, any person that tests positive for the Huntington’s
Disease genetic marker will develop the disease. Id. at 1666.
112. CRG, supra note 102.
113. Id.
114. Id. Other cases include: 1) A seven-year-old boy whose genetic test reveals that he
has a predisposition to a heart disorder was denied insurance on the basis that the genetic
condition qualifies as a preexisting condition; 2) a young boy with Fragile X Syndrome lost his
insurance coverage on the basis that his disability represents a preexisting condition; and 3) a
woman chose not to undergo a BRAC-1 breast cancer screening because she was afraid that
it would jeopardize her chances of getting a promotion. Id.
115. See Sismondo, supra note 110, at 474-75.
116. Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 1260, 1264 (9th Cir. 1998).
117. Id. at 1264-65.
118. Id. at 1269.
119. Id. at 1270.
120. Id.
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Similarly, in E.E.O.C. v. Burlington Northern and Santa Fe Railway
Company, the Equal Employment Opportunity Commission brought a
lawsuit on behalf of current or former Burlington Northern employees
alleging genetic discrimination under 42 U.S.C § 12112(d) and § 12203 of
Title I of the ADA.121 The employees who filed suit alleged that they had
been forced to submit to a blood test in order to locate a genetic marker for
carpal tunnel syndrome.122 Further, they alleged that Burlington Northern
imposed negative consequences for those employees who refused to submit
to the test.123 Burlington Northern agreed to settle and the court ordered
that it pay up to $1,775,000 to the employees.124 Burlington Northern also
agreed to return the genetic samples to the employees.125 Burlington
Northern’s motive was possibly driven by cost; in the year that the case was
filed, Burlington Northern received approximately 125 disability claims from
employees for work-related carpal tunnel syndrome.126
In addition to a claim under the ADA, the plaintiff in Fleming v. State
University of New York also alleged a Fourteenth Amendment constitutional
claim arguing genetic discrimination in violation of due process
protections.127 The plaintiff stated that he voluntarily disclosed his sickle cell
disease to his supervisor after hospitalization.128 Roughly three years later,
the plaintiff applied to and was hired by Yuma Regional Medical Center
(“Yuma”).129 During its credentialing process, the plaintiff claims Yuma
contacted the plaintiff’s supervisors who informed Yuma that the plaintiff
had sickle cell disease.130 The plaintiff claims Yuma questioned him on his
health and asked why he had not disclosed the information to them
directly.131 The plaintiff refused to sign an addendum to his employment
contract, and he believes that such an addendum was part of constructive
termination.132 In finding that the defendants violated the plaintiff’s right to
121. EEOC v. Burlington N. & Santa Fe Ry. Co., No. 02-C-0456, 2002 WL 32155386, at
*1 (E.D. Wis. 2002).
122. Id.
123. Id.
124. Id. at *2.
125. See id. at *3. Burlington Northern agreed to not 1) require its current or former
employees to submit to genetic testing, 2) submit previously obtained blood samples for
genetic testing, 3) analyze previously obtained genetic samples, 4) use any previously
obtained genetic sample, or 5) threaten or take any adverse employment actions because of
the legal proceedings. Id. at *2-3.
126. Sismondo, supra note 110, at 475.
127. Fleming v. State Univ. of N.Y., 502 F. Supp. 2d 324, 327 (E.D.N.Y. 2007).
128. Id. at 326.
129. Id. at 327.
130. Id.
131. Id.
132. Fleming v. State Univ. of N.Y., 502 F. Supp. 2d 324, 327 (E.D.N.Y. 2007).
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privacy under the Fourteenth Amendment, the court noted that sickle cell
disease is a “serious medical condition,” as it exposed the plaintiff to painful
attacks and caused the death of his sister.133 The court further described
that knowledge of sickle cell disease “can expose an individual to
intolerance,” as it has invoked employment and insurance discrimination
since the 1970’s against sufferers and those who show a genetic
predisposition to the disease.134 As such, the court held that the plaintiff’s
right to privacy under the Fourteenth Amendment included the right to
confidentiality with regard to his sickle cell disease.135
Finally, in Jones v. Inter-County Imaging Centers, the plaintiff alleged
genetic discrimination under the ADA and state human rights law.136 There,
the plaintiff claimed that his employer, defendant Inter-County Imaging
Center, offered him a full-time promotion but that while he was out on sick
leave for sickle cell disease, the defendant informed him that the full-time
position had been filled and his previous part-time position had been
eliminated.137 The plaintiff claimed that the defendant terminated his
employment because the Center did not want to continue to pay for the
plaintiff’s medical costs brought on by sickle cell disease.138 While the court
ultimately did not reach the issue of genetic discrimination,139 the plaintiff’s
claim amounted to such an assertion.
VI. PRIOR NON-DISCRIMINATION EFFORTS
Throughout the past several decades, there have been numerous
attempts to limit genetic discrimination by state and federal legislation.
However, such efforts have been anything but comprehensive.140 By 2008,
forty-seven states had enacted laws prohibiting genetic discrimination in
health insurance and thirty-five states restricted employers from adversely
using the information against employees.141 These laws were limited,
however, as they generally only prohibited underwriting for private health
insurance and prohibited the use of genetic information for employment

133. Id. at 341 (citing Doe v. City of N.Y., 15 F.3d 264, 267 (2d Cir. 1994)).
134. Id. at 341, 343.
135. Id. The court rejected the plaintiff’s ADA claim on grounds that Title II did not apply
to employment discrimination. Id. at 346.
136. Jones v. Inter-County Imaging Ctrs., 889 F. Supp. 741, 742 (S.D.N.Y. 1995).
137. Id.
138. Id.
139. Id. at 746 (denying the defendants’ motion to dismiss for failure to state a claim).
140. See Sismondo, supra note 110, at 466-67 (noting that President Clinton signed an
executive order banning genetic discrimination in employment, but it only applied to federal
employees).
141. Mark A. Rothstein, Putting the Genetic Information Nondiscrimination Act in Context,
10 GENETICS MED. 655, 655 (2008).
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decisions.142 Currently, no state law covers genetic discrimination from
employer-sponsored insurance plans,143 which combine to provide the
largest source of insurance coverage in the country.144
While the majority of states have laws prohibiting genetic discrimination,
they lack uniformity and “vary widely with respect to their approach,
application, and level of protection.”145 For example, North Carolina
requires that no “entity shall deny or refuse employment to any person or
discharge any person from employment on account of the person’s having
requested genetic testing or counseling services, or on the basis of genetic
information obtained concerning the person or a member of the person’s
family.”146 Presumably, under North Carolina law it would be permissible
for an employer to require genetic testing as long as the information
obtained is not used against the employee.147 There are likely very few
appropriate reasons for such a request, and at the very least, the request
may amount to breach of privacy and certainly opens the door for genetic
discrimination. Even more shocking, Florida has legislation that only
Therefore, a person’s
protects people with the sickle cell trait.148
predisposition to cancer—or any other illness whatsoever—would be
acceptable grounds for discrimination.
Before GINA, federal law also failed to adequately protect employees
and patients from genetic discrimination. In 1996, Congress enacted the
Health Insurance Portability and Accountability Act (HIPAA), 149 which
amended many provisions of the Employee Retirement Income Security Act
of 1974 (ERISA)150 in order to better protect private health care information

142. Id.
143. See Sara Abiola, The Genetic Information Nondiscrimination Act of 2008: “First Major
Civil Rights Bill of the Century” Bars Misuse of Genetic Test Results, 36 J.L. MED. & ETHICS
856, 857 (2008) (citing National Conference of State Legislatures, Genetics and Health
Insurance State Anti-Discrimination Laws (2008), http://www.ncsl.org/IssuesResearch/Health/
GeneticNondiscriminationinHealthInsuranceLaws/tabid/14374/Default.aspx).
144. Abiola, supra note 143, at 857 (citing Kaiser Comm’n on Medicaid & the Uninsured,
Health Insurance Coverage in America: 2004 Data Update 10 (2005)).
145. GINA, Pub. L. No. 110-223, § 2, 122 Stat. 881, 882.
146. N.C. GEN. STAT. ANN. § 95-28.1A(a) (LexisNexis 2005).
147. § 95-28.1A.(a). The statute does not prohibit employers from requiring genetic
testing or otherwise obtaining genetic information.
148. See Fla. Stat. Ann. § 448.075 (West 2006) (prohibiting employers from denying or
terminating employment because a person has the sickle-cell trait); § 448.076 (prohibiting
mandatory testing or screening for the sickle-cell trait).
149. See Health Insurance Portability and Accountability Act of 1996, Pub. L. 104-191,
110 Stat. 1936, 1936 (1996) (codified in scattered sections of 26 U.S.C., 29 U.S.C., and 42
U.S.C.).
150. See Employee Retirement and Income Security Act of 1974, Pub. L. 93-406, 88 Stat.
829 (1974) (codified at 29 U.S.C. §§ 1001-1461).
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and address genetic discrimination. HIPAA is a federal privacy law
prohibiting the disclosure, and limiting the use, of confidential medical
information.151 Before GINA, HIPAA regulations stated that “a group health
plan . . . may not establish rules for eligibility (including continued eligibility)
of any individual to enroll under the terms of the plan based on . . .
[g]enetic information.”152 This section failed to prohibit the requesting or
requiring of genetic tests, and only applied to employer-based group health
plans.153
HIPAA also prescribes that in the absence of a current medical
diagnosis, the predisposition to a disease cannot be considered a
preexisting condition for the purpose of determining issues relating to
medical insurance. As amended in 2006, “[g]enetic information shall not
be treated as a condition . . . in the absence of a diagnosis of the condition
related to such information.”154 Under HIPAA, insurance companies cannot
use information in genetic tests to determine eligibility or set premium prices
in employer-based or group health plans.155 However, genetic information
could still be used to set premiums and determine eligibility for individuallypurchased plans.156 Further, nothing is mentioned about restrictions placed
on employers.157 Because the provisions of HIPAA have left looming gaps

151. See Goldman, supra note 14, at 93 (citing Jeffrey N. Gibbs, State Regulation of
Pharmaceutical Clinical Trials, 59 Food & Drug L.J. 265, 266 (2004)). HIPAA is an act
“[t]o…improve portability and continuity of health insurance coverage in the group and
individual markets, to combat waste, fraud, and abuse in health insurance and health care
delivery, to promote the use of medical savings accounts, to improve access to long-term care
services and coverage, to simplify the administration of health insurance, and for other
purposes.” HIPAA, 110 Stat. 1936.
152. 29 U.S.C. § 1182(a)(1)(F) (2006).
153. See § 1191b(a)(1) (defining a “group health plan” as “an employee welfare benefit
plan . . . that . . . provides medical care . . . to employees or their dependents”) (emphasis
added).
154. 29 U.S.C. §1181(b)(1)(B) (2006). Not including this specific exception for genetic
information, section 1181(a)(1) states that “a group health plan, and a health insurance issuer
offering group health insurance coverage, may, with respect to a participant or beneficiary,
impose a preexisting condition exclusion only if – (1) such exclusion relates to a condition
(whether physical or mental), regardless of the cause of the condition, for which medical
advice, diagnosis, care, or treatment was recommended or received within the 6-month
period ending on the enrollment date.” 29 U.S.C. §1181(a)(1).
155. § 1182(b) (prohibiting group health plans from charging any person a higher
premium based on “any health status-related factor,” compared to a “similarly situated
individual enrolled in the plan”).
156. Such plans fall outside the scope of the HIPAA protections discussed. See infra notes
169 and 172.
157. See generally 29 U.S.C. §§ 1181-82 (applying only to group health plans and
“health insurance issuer[s] offering group health insurance coverage”).
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in private insurance plans and employment decision regulations, the breadth
of this Act does not adequately prevent genetic discrimination.
While the Americans with Disabilities Act (ADA) has been cited in genetic
discrimination cases, it was not enacted for that purpose and therefore gives
little protection in the workplace. The following excerpt summarizes the
influence of the ADA on genetic discrimination:
The ADA states that “[n]o covered entity shall discriminate against a
qualified individual with a disability because of the disability of such
individual in regard to job application procedures, the hiring, advancement,
or discharge of employees, employee compensation, job training, and other
terms, conditions, and privileges of employment.” Thus, to pursue a genetic
discrimination claim under the ADA, genetic traits must fall within the ADA’s
definition of disability. To be considered a disability under the ADA, a
genetic trait must be “a physical or mental impairment that substantially
limits one or more of the major life activities[;] . . . a record of such
impairment; or . . . being regarded as having such an impairment.” Since
genetic traits tend to cause impairment in the future, the United States
Supreme Court has suggested that genetic traits do not sufficiently meet the
interpreted requirement that a disability be currently present. Consequently,
genetic traits likely fall outside of the ADA’s definition of disability.158

Because the definition of “disability” requires that impairments have
substantial limits on life activities, it would be difficult to prove that an
employer acted adversely based on a person’s genetic information without
some outward showing of symptoms.159 Thus, a genetic predisposition to a
disease would fall outside of the scope of “disability” and discrimination
under the ADA. Similar to HIPAA, the ADA left too much room for “lawful”
genetic discrimination and is still too broad to adequately protect
employees.160
Other genetic discrimination claims have been founded under Section
504 of the Rehabilitation Act.161 The Rehabilitation Act states that “[n]o

158. Paul D. Trumble, “Knickel” and Dime Issues: An Unexplored Loophole in New York’s
Genetic Discrimination Statute and the Viability of Genetic Testing in the Sports Employment
Context, 70 ALB. L. REV. 771, 777 (2007) (internal citations omitted). See also Americans with
Disabilities Act, 42 U.S.C. § 12112(a) (2006).
159. Jeremy A. Colby, An Analysis of Genetic Discrimination Legislation Proposed by the
105th Congress, 24 AM. J.L. & MED. 443, 466-67 (1998).
160. See id. at 467 (concluding that the ADA offers little protection in the absence of a
favorable judicial interpretation). See also, Sismondo, supra note 110, at 467 (noting the
ADA’s broad language, its failure to expressly cover genetic discrimination, and the absence
of any court decision recognizing that it extends to genetic information).
161. See, e.g., Fleming v. State Univ. of N.Y., 502 F. Supp. 2d 324, 334-39 (E.D.N.Y.
2007) (holding that the plaintiff stated a valid claim under section 504 of the Rehabilitation
Act after the plaintiff was allegedly constructively terminated after his employer discovered he
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otherwise qualified handicapped individual . . . shall, solely by reason of her
or his disability, be excluded from participation in, be denied the benefits of,
or be subjected to discrimination under any program or activity receiving
Federal financial assistance.”162 The major limitation of the Rehabilitation
Act is obvious; only employees of federally funded institutions or programs
are protected from genetic discrimination.163
Finally, the Fourteenth Amendment has been used as a vehicle for
genetic discrimination claims.
Plaintiffs may claim that genetic
discrimination is a breach of privacy under the Fourteenth Amendment and
hold the defendant liable under 42 U.S.C. § 1983.164 Section 1983 states
that an action can be brought against any “person who, under color of any
statute, ordinance, regulation, custom, or usage, of any State . . . subjects,
or causes to be subjected, any citizen of the United States or other person
within the jurisdiction thereof to the deprivation of any rights, privileges, or
immunities secured by the Constitution and laws.”165 This claim is likely
centered on a broad argument of privacy and, similar to the other failed
non-discrimination efforts, it is not specific enough to entirely shield against
many types of genetic discrimination.
Although state laws, ERISA, HIPAA, the ADA, the Rehabilitation Act, and
the Fourteenth Amendment have allowed for some protection against
genetic discrimination in employment and the insurance industry, such an
inconsistent and broad assembly of legislation has failed to adequately
address specific cases of genetic discrimination. Finally, in 2008, Congress
responded to earlier legislative short-comings and adopted the Genetic
Information Nondiscrimination Act of 2008 as the primary vehicle to
combat genetic discrimination.

had sickle cell anemia). See also supra notes 127-35 and accompanying text (discussing
Fleming).
162. Rehabilitation Act of 1973, Pub. L. 93-112, § 504, 87 Stat. 355, 394 (codified at 29
U.S.C. § 794(a) (2006)).
163. See 29 U.S.C. § 794(d) (“The standards used to determine whether this section has
been violated in a complaint alleging employment discrimination…shall be the standards
applied under…the Americans with Disabilities Act of 1990…, as such sections relate to
employment.”); See also Fleming, 502 F.Supp.2d at 334-37 (finding the ADA’s prohibition of
discrimination based on medical examinations and inquiries applicable in an employment
discrimination case under the Rehabilitation Act).
164. See U.S. CONST. amend. XIV, § 1 (“No State shall make or enforce any law which
shall abridge the privileges or immunities of citizens of the United States; nor shall any State
deprive any person of life, liberty, or property, without due process of law; nor deny to any
person within its jurisdiction the equal protection of the laws.”).
165. 42 U.S.C. § 1983 (2006).
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VII. THE GENETIC INFORMATION NONDISCRIMINATION ACT OF 2008 (GINA)
Congress has long been aware of genetic discrimination and its
negative impact on genetic research participant recruitment.166
Congresswoman Louise Slaughter (D, NY) introduced the first genetic nondiscrimination bill in the 104th Congress in 1995, and similar bills were
introduced in the 105th, 106th, 107th, 108th, and 109th Congresses.167
Finally, after thirteen years, the Genetic Information Nondiscrimination Act
of 2008 was signed into law by President Bush on May 21, 2008 during the
110th Congress.168 The Act brings much needed and anticipated uniformity
to the prohibition of genetic discrimination in employment and health
insurance. To prohibit discriminatory uses of genetic information in making
employment and health insurance decisions, GINA amends previous federal
legislation, including ERISA, the Public Health Service Act (PHSA), the
Internal Revenue Code of 1986, and Title XVIII of the Social Security Act
(SSA).169 It also seeks consistency with Title VII of the Civil Rights Act of
1964, HIPAA, and the ADA.170 While GINA provides more consistent and

166. Kathy L. Hudson et al., Keeping Pace with the Times – The Genetic Information
Nondiscrimination Act of 2008, 358 NEW ENG. J. MED. 2661, 2662 (2008) (quoting
cosponsor Senator Ted Kennedy: “Discrimination in health insurance and the fear of potential
discrimination threaten both society’s ability to use new genetic technologies to improve
human health and the ability to conduct the very research we need to understand, treat, and
prevent genetic disease”).
167. H.R. REP. NO. 110-28, pt. 1, at 23 (2007).
168. See GINA, Pub. L. No. 110-233, 122 Stat. 881, 881, 922 (2008).
169. See GINA § 101, 122 Stat. at 883-88 (amending ERISA); § 102, 122 Stat. at 88896 (amending the PHSA); § 103, 122 Stat. at 896-99 (amending the I.R.C.); § 104, 122 Stat.
at 899-903 (amending the SSA). Many provisions of Title I and II look strikingly similar to the
consent order/settlement agreement in EEOC v. Burlington Northern & Santa Fe Railway Co.,
No. 02-C-0456, 2002 WL 32155386, at *3 (E.D. Wis. 2002). There, as part of equitable
relief, the court prohibited Burlington Northern from requiring or requesting genetic testing
from current or former employees or threatening adverse employment actions based on
genetic test results. Id.
170. See, e.g., H.R. REP. NO. 110-28, at 35 (“As a guiding principle, [GINA] is designed
to extend to individuals in the area of genetic discrimination the same procedures and
remedies as are provided under Title VII of the Civil Rights Act of 1964.”). Provisions
regarding the confidentiality of genetic information are “intended to be consistent with the
ADA’s requirements regarding the maintenance and treatment of medical information.” H.R.
REP. NO. 110-28, at 35. H.R. REP. NO. 110-28, at 67 (noting attempts to resolve a conflict
between GINA and HIPAA regarding the types of information “that can be permissibly shared
between HIPAA covered entities”). See also Civil Rights Act of 1964, Pub. L. 88-352, 78 Stat.
241, 253 (1964) (codified as amended at 42 U.S.C. §§ 2000e-2000e-17 (2006)); HIPAA,
Pub. L. 104-191, 110 Stat. 1936, 2073 (1996); Americans with Disabilities Act, 42 U.S.C. §§
12101-12213 (2006).
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universal non-discrimination protection, it does not preempt more protective
state genetic non-discrimination legislation.171
GINA is divided into two titles: Title I prohibits discrimination in health
insurance and Title II prohibits discrimination in employment. Under Title I,
GINA prohibits all health insurers from using genetic information as a
means of setting eligibility or premiums, and from requesting or requiring
genetic tests.172 Genetic information with respect to any individual is
defined as “information about such individual’s genetic tests, the genetic
tests of family members of such individual, and the manifestation of a
disease or disorder in family members of such individual.”173 Genetic test is
defined as “an analysis of human DNA, RNA, chromosomes, proteins, or
metabolites, that detects genotypes, mutations, or chromosomal
changes.”174 These provisions include genetic information and testing with
respect to the insured’s dependants, or any other first-degree, seconddegree, third-degree, or fourth-degree relatives.175
Title II of GINA restricts employers from using genetic information to
make employment decisions and also restricts them from requesting,
purchasing, or requiring genetic information about a prospective employee,
current employee, or the employee’s family members.176 These restrictions
also apply to employment agencies, labor organizations, and those in
charge of job training programs.177
VIII. LEGISLATION LIMITATIONS AND RACIAL DISPARITY
Unfortunately, the reading of GINA’s plain text may result in unintended
consequences. With regard to health insurance, because GINA does not
allow health insurers to request or require genetic tests, some individuals
may not receive medical coverage and treatment in dangerous situations.178
Similarly, this same prohibition does not allow health insurers to recommend
a genetic test for preventive screening, confirming a medical diagnosis, or

171. See Abiola, supra note 143, at 856.
172. GINA, Pub. L. No. 110-233, §§ 101(a)-101(b), 122 Stat. 881, 883-85 (2008). See
also Hearing, supra note 106, at 44 (“The bill would explicitly allow researchers, for the first
time, to tell research participants that it is simply against the law for health insurers or
employers to use genetic information to discriminate.”).
173. GINA, Pub. L. No. 110-233, § 101(d), 122 Stat. at 885-86.
174. § 101(d), 122 Stat. at 885-86.
175. §§ 101(a)(3), 101(b), 122 Stat. at 883.
176. §§ 202(a)-(b), 122 Stat. at 907.
177. §§ 204-06, 122 Stat. at 910-14.
178. H.R. REP. NO. 110-28, pt. 1, at 66-67 (2007) (giving the example of a patient with
hepatitis C: some viral genotypes require longer treatment and unless the health insurer
requests a genetic test to determine the genotype, the patient may not receive adequate
therapy).
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predicting a response to therapy (which consequently is the major goal of
PGx).179 These consequences could become significant obstacles to health
insurers’ access to medical information, and in effect, patients’ access to
care.180 In employment, the minority view of Republicans on the Committee
on Education and Labor was that Title II could lead to an increase in
frivolous lawsuits against employers due to the availability of punitive and
compensatory damages.181 The minority view of the Committee on Energy
and Commerce cites a more general problem. Title II, the Committee
claims, is too broad and sweeping in that it reaches practically every entity,
corporation, foundation, and agency that has contact with employees.182
Extending beyond GINA’s possible unintended consequences, the
legislation has another and likely more crucial limitation in achieving its
legislative aim. The purpose of GINA is to “establish[ ] a national and
uniform basic standard . . . to fully protect the public from discrimination
and allay their concerns about the potential for discrimination, thereby
allowing individuals to take advantage of genetic testing, technologies,
The question remains: will GINA
research, and new therapies.”183
encourage and allow individuals to participate in PGx research and clinical
opportunity? Likely, GINA has somewhat quelled the genetic discrimination
“fear factor” when it comes to patients’ decisions about participating in
genetic research and having the results attached to them for the rest of their
lives. However, in order to gain the full benefits of PGx research and its
applications, Congress and the research communities may need to realize
that the fear of genetic discrimination is not the only “fear factor” patients
and individuals face. Further, with the specific need for genotypically
diverse minority populations, there may be a much more significant hurdle
to fully realizing the scope of PGx than the fear of genetic discrimination.
While genetic discrimination may be unique to genetic research, it is not
the only risk participants and patients associate with general clinical
research. Risk is defined as “the chance of injury, damage, or loss”184 and
is mostly subjective, formed through psychological, social, emotional,

179. H.R. REP. NO. 110-28, at 67.
180. H.R. REP. NO. 110-28, at 67.
181. H.R. REP. NO. 110-28, at 67-68.
182. See H.R. REP. NO. 110-28, pt. 3, at 66-67 (2007). “Title II [of GINA] . . . covers
employers from the FBI to NASA to laboratories, to State and local governments, to nuclear
power plants, to hospitals, and many more. Title II restricts information flow in numerous
settings from employers involved in responses to pandemic flu outbreaks, to employers
involved in judicial proceedings, to health and safety monitoring, and to employers
administering or sponsoring benefits.
We cannot today easily imagine all of the
circumstances.” H.R. REP. NO. 110-28, at 66.
183. GINA, Pub. L. No. 110-233, § 2, 122 Stat. 881, 882-83 (2008).
184. Slovic, supra note 8, at 62 (citation omitted).
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cultural, and political means.185 Whether the risk is real or subjective, the
fear of such risk is absolutely real, and with respect to genetic research,
Americans likely perceive numerous social and psychological risks that go
well beyond genetic discrimination.186 These risks include the fear of
learning harmful genetic information about oneself, the risk that the learning
genetic information may have a negative impact on genetically related
family members, the fear that genetic testing is too risky and confusing, as
well as numerous others.187 Thus, these perceived risks should not be
overlooked by the research community as hurdles to furthering genetic
research and PGx participation.188
The receipt of genetic information can be psychologically harmful to
research and clinical participants in several ways.189 Simply learning that
one is predisposed to a genetic disease or is certain to become afflicted with
a disease in the future can be injurious to one’s overall well-being.190 Such
information is likely to cause worry and be emotionally upsetting either
because it makes the participant’s future uncertain, or because it makes it
firmly certain.191 Additionally, a participant’s predisposition to certain
diseases is measured in probabilities; therefore the prediction will not come
to fruition in many cases, causing some to worry that they will waste
valuable time and energy worrying for no reason.192 Some people even
report that they would rather just not know about their genetic make-up than
learn that they have a genetic predisposition to a certain disease or
cancer.193

185. See id. at 67 (“Recent studies have shown that factors such as gender, race, political
worldviews, affiliation, emotional affect, and trust are strongly correlated with risk
judgments.”).
186. See Schoonmaker & Williams, supra note 3, at 22-25 (discussing how genetic
information and testing can lead to many undesired outcomes).
187. Id. at 23-24 (stating that two additional fears include the fear of being convicted of a
crime, and the fear of discovering that the person tested is not actually the biological relative
of a family member).
188. See generally Slovic, supra note 8, at 60 (discussing that research participants and
researchers often have differing views of risk and therefore people are generally not swayed by
researchers’ recitations of risk statistics).
189. See Henderson et al., supra note 2, at 196 (noting that concerns about genetic
research included “knowing too much,” “knowing what conditions we [have to face],”
“realizing there is no treatment or prevention,” and “worrying”).
190. See DEP’T OF HEALTH & HUMAN SERV., Office for Human Research Protections,
Institutional Review Board Guidebook, Chapter V, http://www.hhs.gov/ohrp/irb/irb_chapter
5ii.htm#h12 (last visited March 12, 2010).
191. See id.
192. See id.
193. See Henderson et al., supra note 2, at 196.
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Family plays a definite role in genetic research risk. A recent literature
review of studies found that people with a family history of a genetic disease
consented to participate in genetic research at lower overall rates.194
Logically, the lower consent rate may correspond to the participants’ fears of
learning genetic information about themselves. Learning one’s own
predisposition to a disease, genotype variation, or disease marker can be
equally detrimental to family members’ well-being, especially if the genetic
information can be inherited.195
Because of the significant importance of including ethnically and racially
diverse groups in PGx research, it is crucial to understand the unique
perceived risks that these populations face in genetic research. This
importance stems from the fact that minority populations are often
underrepresented in clinical drug trials compared to the surrounding
community.196 One researcher found that out of thirteen studies of drug
efficacy and safety of hypertensive drugs, only eight had at least one African
American.197 Making participation even more difficult is that as a group,
African Americans have been found to have less positive views about
genetic research than Caucasians.198 Several empirical studies have
supported that African-American and ethnic minorities are less likely to
consent to genetic testing.199 In one study, as compared to whites, AfricanAmerican and Hispanic participants reported significantly higher levels of

194. Rene Sterling, et al., Public Willingness to Participate in and Public Opinions About
Genetic Variation Research: A Review of the Literature, 96 AM. J. PUB. HEALTH 1971, 1976
(2006).
195. See SCHOONMAKER & WILLIAMS, supra note 3, at 23-24.
196. Noah, supra note 7, at 225-26 (discussing that in a 1989 analysis of clinical trials,
African Americans were underrepresented in twenty-three out of thirty-five clinical trials for
which racial data was available).
197. Id. at 226.
198. Henderson et al., supra note 2, at 196; see generally Slovic, supra note 8, at 76
(discussing that, compared with white males, “nonwhite men see the world as more dangerous
because in many ways they are more vulnerable, because they benefit less from many of its
technologies and institutions, and because they have less power and control over what
happens in their communities and their lives”).
199. See, e.g., Hillary R. Bogner et al., Personal Characteristics of Older Primary Care
Patients Who Provide a Buccal Swab for Apolipoprotein E Testing and Banking of Genetic
Material: The Spectrum Study, 7 CMTY. GENETICS 202, 207 (2004) (finding that “patients 80
years and older and African-Americans were less likely to provide a buccal swab than other
older patients”; Geraldine M. McQuillan et al., Consent for Genetic Research in a General
Population: The NHANES Experience, 5 GENETICS MED. 35, 37 (2003) (finding that the lowest
consent rates for genetic research were provided by non-Hispanic blacks); Patricia G.
Moorman et al., Racial Differences in Enrollment in a Cancer Genetics Registry, 13 CANCER
EPIDEMIOLOGY BIOMARKERS & PREVENTION 1349, 1349 (2004) (finding much lower enrollment
rates for African-American women in a cancer genetics registry).
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fear of racial discrimination than European Americans.200 The same study
showed that African Americans reported a higher percentage of concern of
unequal economic access to benefits.201 Also, a smaller percentage of
African Americans named the prevention and treatment of disease as a
perceived benefit of genetic research.202
Trust is likely one of the most important risk barrier between AfricanAmerican participants and genetic research. According to a recent survey,
the rate of mistrust among African Americans as compared to whites is
staggering. A survey population comprised of 527 African Americans and
382 whites was polled to examine racial differences regarding distrust of
research and the medical community, wherein “distrust” was defined as
“lack of agreement with a statement of trust.”203 The survey revealed that
African Americans are less likely to trust that their physician would fully
describe research participation, less likely to believe that they could freely
ask their physician questions, more likely to disagree that their physician
would not ask them to participate in research if the physician thought there
was harm, more likely to believe that their physician exposed them to
unnecessary harm, and more likely to believe that someone like them would
be used as a guinea pig without his or her consent.204 The results also
showed that a higher percentage of African-American participants believed
that physicians have prescribed medication or given them treatment as a
way of experimenting on them without their consent.205 The authors of the
study concluded that past and present racial experiences may contribute
significantly to African Americans’ mistrust of the medical and research
community.206
There are several reasons for African Americans’ mistrust of medicine
and research, many of which seemingly stem from historically unequal
treatment. Slaves were sometimes forced into roles as research subjects so
200. Benjamin R. Bates et al., Warranted Concerns, Warranted Outlooks: A Focus Group
Study of Public Understandings of Genetic Research, 60 SOC. SCI. & MED. 331, 335 (2005)
(“Participants were 58 African Americans, 26 European Americans, and 7 Hispanics.”).
201. Id. at 336. 11.5% of African Americans were concerned about unequal economic
access to benefits, as compared to 8.6% of European-Americans and 3.8% of HispanicAmericans. Id.
202. Id at 339. Only 67% of African Americans reported that the prevention and
treatment of genetic diseases is a benefit to genetic research, while 81.8% of EuropeanAmericans reported the same. Id.
203. See Corbie-Smith et al., supra note 9, at 2459.
204. Id.at 2460. See also Giselle Corbie-Smith et al., Attitudes and Beliefs of African
Americans Toward Participation in Medical Research, 14 J. GEN. INTERNAL MED. 537, 539-40
(1999) [hereinafter Attitudes and Beliefs] (discussing that African-American participants to
another survey reported fear of being used as “guinea pigs” and “being experimented on”).
205. See Corbie-Smith et al., supra note 9, at 2460.
206. See id. at 2462.
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that researchers could study sunstroke, surgical techniques, and postmortem
dissection.207 Further, the infamous Tuskegee study has helped continue the
trend of mistrust in recent decades.208 Even though some potential AfricanAmerican research participants have inaccurate knowledge about the study,
many have nonetheless referenced the study as a reason for researcher
mistrust.209 Regardless of the accuracy of their beliefs, their version of the
study is what they believe to be “real.”210 Some African Americans even
believe that a government conspiracy was to blame for the results of the
Tuskegee study and that such a conspiracy exists to this day and is
responsible for introducing HIV into the African-American community.211
Even more daunting for PGx research in particular is that African Americans
report the highest levels of mistrust in studies and trials involving the
collection of DNA.212
State legislation has also helped fuel historical mistrust. In the 1970’s,
some states enacted laws requiring African Americans to undergo genetic
tests indicating markers for sickle cell anemia.213 Such laws heightened
racial discrimination and scrutiny.214 Whatever the reason may be for
mistrust among various African-American communities and individuals,
without trust, no level of communication between researchers and AfricanAmerican participants may be adequate for research recruitment. In other
words, if the African-American participant does not trust the research and
medical community, he or she may not trust the researchers’ positive
assertions about genetic research, its benefits, or its minimal risk, and
therefore may not participate.
Other risks and barriers to minority recruitment for genetic research exist
and should not be ignored. Such factors include financial barriers, attitudes
of treating physicians, pharmaceutical company involvement, and health
illiteracy.215 Further, while it is not a perceived risk per se, a certain barrier
207. Noah, supra note 7, at 229.
208. See id. at 229-30. Participants of the study included 400 African Americans who
were believed to have syphilis. The study was designed to investigate the natural development
of the disease over time. When the study began in the 1930s, there was no known cure for
syphilis. However, once penicillin was discovered to be an effective treatment, the
investigators failed to inform the study participants that there was a cure. Id.
209. See Attitudes and Beliefs, supra note 204, at 543.
210. Id.
211. Noah, supra note 7, at 230.
212. See Cathrine Hoyo, Barriers and Strategies for Sustained Participation of AfricanAmerican Men in Cohort Studies, 13 ETHNICITY & DISEASE 470, 472 (2003).
213. GINA, Pub. L. No. 110-233,§ 2, 122 Stat. 881, 882 (2008) (codified at 26 U.S.C.,
29 U.S.C. § 2000ff).
214. § 2, 122 Stat. at 882. In response, Congress passed the National Sickle Cell Anemia
Control Act, Pub. L. No. 92-294, 86 Stat. 136-39 (1972).
215. See Noah, supra note 7, at 226-28.
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to African-American research participation is lack of scientific and medical
Unfortunately, this barrier is confounded by the
understanding.216
presumption that race is correlated with lower socio-economic status and
education, both of which correlate with lower health status.217
IX. ADDRESSING RACIAL DISPARITIES IN PGX RESEARCH AND CLINICAL
OPPORTUNITY
In order for PGx to reach its full potential, African-American populations
must be included in clinical drug trials so that the link between race and
genetic variation can be better understood. Only then can this population
benefit from the clinical applications of PGx research. In order for this to
occur, however, more focus must be placed on identifying risks important to
the specific study population, and on educating the public about risks and
their truthful relation to genetic research. While numerous methods for
achieving this goal have been suggested, many scholars support some form
of “community-based review” as a useful vehicle for public education.218
Community review involves aspects of “community approval, group consent,
communal discourse, and other methods of consulting with communities
about the potential implications of genetic research.”219
From the researchers’ perspective, community involvement will help form
a long-term relationship and allow researchers to better understand risks
facing the research participants.220 Specifically, constructive dialogue can
identify both perceptions of PGx and the public’s willingness to participate in
clinical research.221 Such a dialogue has begun with regard to African
Americans’ views on ways to improve participation in research.222
Participants of the dialogue “expressed the need for more honest and
respectful communication from physicians and other research personnel,
and the importance of providing complete information about risk and
benefits of research.”223 The participants of this survey also suggested it
would be beneficial to have time to research the study implications on their
own and talk to family and friends about such implications.224 Further
suggestions included more education and promotion of awareness of the
216. Id. at 228.
217. Id. at 229.
218. See e.g., Richard R. Sharp & Morris W. Foster, Involving Study Populations in the
Review of Genetic Research, 28 J.L. MED. & ETHICS 41, 42 (2000).
219. Id. (noting that “[i]n its least demanding form, community review could be little more
than informal dialogue between researchers and members of the study population”).
220. Id.
221. See HHS, supra note 10, at 8.
222. See Attitudes and Beliefs, supra note 204, at 541.
223. Id.
224. Id.
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purpose of research.225 Once researchers fully understand the cultural
values and perceived risks and attitudes toward genetic research, they can
create community-tailored recruitment strategies and research designs.
Because researcher and physician mistrust is one of the most cited
barriers to minority research participation, establishing cultural trust must be
a primary objective of community review. Researcher knowledge and
participant mistrust are inevitably intertwined, and as such, building trust
should include all facets of community involvement, such as engagement,
dialogue, and feedback.226 Based on information from African-American
participants, one study suggested identifying civil organizations in the
community, the head of which could operate as a “gate keeper” between
the researcher and possible participants.227 In this model, “clusters” of
participants would be identified within the civic organizations and the
gatekeeper of the organization would approach individuals in the cluster
about research participation.228 Recommended civic organizations included
churches, fraternity and sorority organizations at Historically Black Colleges
and Universities (HBCU), Partners Against Crime, various women’s
organizations, and the American Legion.229 The study also suggested that
African-American trust would increase if the researchers themselves were
African American.230
Researchers should be cautious, however, not to offend or alienate
minority participants, as differing experiences have left many African
Americans vulnerable. In opening a community dialogue, researchers
should be careful not to label individuals as belonging to a particular group
or base their discussions on an assumption that all members of the group
have the same concerns and beliefs.231 Additionally, researchers should
ensure that any conversations take the form of a dialogue, such that there is
the ability for questions and answers, as opposed to a monologue where the
researcher gives a convoluted “presentation” of research benefits and
risks.232 With such careful consideration and assessment, genetic research
participation risks and barriers can be identified and addressed in order that
PGx can bring safe and effective medicine to the entire American
population.

225.
226.
227.
228.
229.
230.
231.
232.

Id. at 542.
See Corbie-Smith et al., supra note 9, at 2462.
Hoyo, supra note 212, at 473.
See id.
See id. at 473-74.
Id. at 474.
See Noah, supra note 7, at 230-31.
See id.
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X. CONCLUSION
Researchers, pharmaceutical companies, and scholars agree that PGx
has the potential to greatly impact the future of medicine by producing safe,
efficient, and cost-effective drugs. With continued increases in research
participation and public interest among diverse racial, ethnic, and genetic
backgrounds, the long-terms goals of PGx research will likely be exceeded.
GINA has certainly allowed research to continue its forward progress by
alleviating or reducing participants’ fears of genetic discrimination by
insurance companies and employers. This federal law was greatly needed
to add consistency to fragmented state laws and give more severe penalties
to those employers and insurers who discriminate against research
participants.
However, the failure of legislation to recognize the numerous other
psychological and social risks associated with genetic research in the
African-American community will thwart the forward progress of PGx
research and implementation. While GINA has taken a substantial step
forward in eliminating genetic discrimination and thus calming some of the
American public’s fears, PGx research will only reach its full clinical
potential when other risks are clearly identified and addressed through
various forms of community review and involvement.
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